查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1482443

传染病体外诊断市场：依地区：全球产业分析、规模、占有率、成长、趋势、预测，2024-2031

Infectious Disease In-vitro Diagnostics Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 250 Pages | 商品交期: 2-5个工作天内

价格
简介目录

持久性市场研究对全球传染病体外诊断 (IVD) 市场进行了广泛分析，深入瞭解市场趋势、成长动力、课题和新兴趋势。该报告提供了详细的数据和统计数据以引导市场格局，并为利害关係人提供全面的指南。

在全球传染病疫情数量增加的背景下，预计2024年至2031年全球传染病体外诊断市场将大幅成长。该市场预计将从 2024 年的 668 亿美元成长到 2031 年的 902 亿美元，期间复合年增长率为 4.4%。

重要见解

  • 预计市场价值（2024年）：668亿美元
  • 预计市值（2031年）902亿美元
  • 全球市场成长率（2024-2031年复合年增长率）：4.4%

传染病体外诊断市场 - 报告范围

体外诊断在传染病的检测和管理中发挥重要作用，为有效的患者护理提供快速、准确的结果。该市场包括广泛的诊断测试，例如分子测定、免疫测定和旨在检测各种传染源（例如细菌、病毒和寄生虫）的护理点测试。

在全球化、都市化和抗菌素抗药性等因素的推动下，传染病发生率不断上升，推动了对诊断测试的需求。此外，持续的 COVID-19 大流行凸显了强大的诊断基础设施和检测能力对于限制疾病传播和管理公共卫生危机的重要性。

市场成长动力：

有几个因素促进了传染病体外诊断市场的成长，包括爱滋病毒/爱滋病、结核病、疟疾和肝炎等传染病等传染病率的上升。此外，新传染源的出现和现有病原体的重新出现对公共卫生提出了重大课题，需要增强诊断能力。

分子诊断、新一代定序和快速护理点检测等诊断技术的进步使得更快、更准确地检测传染性病原体成为可能。此外，医疗保健支出的增加、政府控制传染病的努力以及人们对早期诊断重要性的认识不断提高，都进一步推动了市场的成长。

市场限制因素：

儘管成长前景乐观，传染病体外诊断市场仍面临一定的课题，包括监管障碍、报销问题和供应链中断。对诊断测试批准和报销限制的严格监管要求可能会抑制製造商，特别是中小型企业进入市场。

此外，实施诊断测试基础设施的复杂性和成本为市场扩张带来了课题，特别是在资源有限的环境中。此外，测试表现的变化以及假阳性和假阴性的可能性可能会影响诊断准确性和患者结果，从而引起医疗保健提供者和患者的担忧。

市场机会：

传染病体外诊断市场提供了大量的创新和扩张机会，特别是在新型诊断技术和测试平台的开发方面。分子诊断学的进步，包括核酸扩增测试和多重检测，正在提高传染病检测的敏感度、特异性和周转时间。

此外，将人工智慧和机器学习演算法整合到诊断平台中可以增强数据分析和解释，从而获得更准确和可操作的诊断见解。此外，更多地采用现场检测和分散诊断解决方案将能够及时诊断和治疗，特别是在服务不足和偏远地区。

本报告解决的关键问题

  • 2024年至2031年传染病体外诊断市场的预期CAGR值为何？
  • 推动传染病体外诊断市场成长的关键因素是什么？
  • 哪个地区在传染病体外诊断市场中占据最大的市场占有率？
  • 全球传染病体外诊断市场的主要参与者有哪些？
  • 主要参与者正在采取哪些策略来维持传染病体外诊断市场的成长？

目录

第一章执行摘要

第二章市场概况

  • 市场范围/分类
  • 市场定义/范围/限制

第三章市场背景

  • 市场动态
  • 情景预测
  • 机会图分析
  • 产品生命週期分析
  • 投资可行性矩阵
  • PESTLE 与 Porter 分析
  • 监管状况
  • 区域母公司市场展望

第四章 全球传染病体外诊断市场分析

  • 过去的市场规模（金额）分析，2019-2023
  • 目前和未来市场规模（金额）预测，2024-2031

第 5 章：依产品类型划分的全球传染病体外诊断市场分析

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023
  • 当前和未来市场规模（金额）分析和预测，2024-2031
    • 机器
    • 试剂
    • 服务
  • 2019-2023年年成长趋势分析
  • 2024-2031年绝对回报机会分析

第六章：全球传染病体外诊断市场技术分析

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023
  • 当前和未来市场规模（金额）分析和预测，2024-2031
    • 免疫测定法
    • 分子诊断
    • 微生物学
    • 其他技术
  • 2019-2023年年成长趋势分析
  • 绝对回报机会分析，2024-2031

第七章依应用：全球传染病体外诊断市场分析

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023
  • 当前和未来市场规模（金额）分析和预测，2024-2031
    • 抗甲氧西林金黄色葡萄球菌
    • 链球菌
    • 艰难梭菌
    • 呼吸道病毒
    • 结核病和抗药性结核病
    • 淋病
    • HPV病毒
    • 爱滋病
    • C型肝炎
    • B型肝炎
    • COVID-19
    • 其他应用
  • 2019-2023年年成长趋势分析
  • 2024-2031年绝对回报机会分析

第 8 章：依最终用途划分的全球传染病体外诊断市场分析

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023
  • 当前和未来市场规模（金额）分析和预测，2024-2031
    • 注意事项
    • 中央研究所
    • 其他用途
  • 2019-2023年年成长趋势分析
  • 2024-2031年绝对回报机会分析

第九章依地区划分：全球传染病体外诊断市场分析

  • 介绍
  • 过去的市场规模（金额）分析，2019-2023
  • 当前市场规模（金额）分析与预测，2024-2031
    • 北美
    • 拉丁美洲
    • 欧洲
    • 亚太地区
    • 中东和非洲
  • 区域市场吸引力分析

第十章 北美传染病体外诊断市场分析（依国家）

第十一章 拉丁美洲传染病体外诊断市场分析（依国家）

第十二章欧洲传染病体外诊断市场分析（依国家）

第十三章亚太传染病体外诊断市场分析（依国家）

第十四章中东和非洲传染病体外诊断市场分析（依国家）

第十五章 主要国家传染病体外诊断市场分析

  • 美国
  • 加拿大
  • 巴西
  • 墨西哥
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 俄罗斯
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯联合酋长国
  • 以色列

第16章市场结构分析

  • 比赛仪表板
  • 竞争标桿
  • 主要参与者的市场占有率分析

第 17 章 竞争分析

  • 衝突详情
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Abbott
    • Quidel Corporation
    • OraSure Technologies, Inc
    • Hologic Inc.
    • Cepheid
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.

第 18 章使用的假设和首字母缩略词

第19章研究方法论

简介目录
Product Code: PMRREP33205

Persistence Market Research presents an extensive analysis of the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing insights into market dynamics, growth drivers, challenges, and emerging trends. This report serves as a comprehensive guide for stakeholders, offering detailed data and statistics for navigating the market landscape.

The global infectious disease in-vitro diagnostics market is poised for significant growth between 2024 and 2031, driven by the increasing prevalence of infectious diseases worldwide. With a projected CAGR of 4.4% during this period, the market is estimated to expand from USD 66.8 billion in 2024 to USD 90.2 billion by 2031.

Key Insights:

  • Estimated Market Value (2024): USD 66.8 Billion
  • Projected Market Value (2031): USD 90.2 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.4%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

In-vitro diagnostics play a crucial role in the detection and management of infectious diseases, providing rapid and accurate results for effective patient care. The market encompasses a wide range of diagnostic tests, including molecular assays, immunoassays, and point-of-care tests, designed to detect various infectious agents such as bacteria, viruses, and parasites.

The increasing incidence of infectious diseases, fueled by factors such as globalization, urbanization, and antimicrobial resistance, drives the demand for diagnostic testing. Furthermore, the ongoing COVID-19 pandemic has underscored the importance of robust diagnostic infrastructure and testing capabilities to control disease spread and manage public health crises.

Market Growth Drivers:

Several factors contribute to the growth of the infectious disease IVD market, including the rising incidence of infectious diseases such as HIV/AIDS, tuberculosis, malaria, and hepatitis. Additionally, the emergence of new infectious agents and the re-emergence of existing pathogens pose significant public health challenges, necessitating enhanced diagnostic capabilities.

Advancements in diagnostic technologies, including molecular diagnostics, next-generation sequencing, and rapid point-of-care testing, enable faster and more accurate detection of infectious agents. Moreover, increased healthcare spending, government initiatives to combat infectious diseases, and growing awareness about the importance of early diagnosis further drive market growth.

Market Restraints:

Despite its positive growth outlook, the infectious disease IVD market faces certain challenges, including regulatory hurdles, reimbursement issues, and supply chain disruptions. Stringent regulatory requirements for diagnostic test approval and reimbursement limitations can hinder market access for manufacturers, particularly small and medium-sized enterprises.

Furthermore, the complexity and cost of implementing diagnostic testing infrastructure, especially in resource-limited settings, pose challenges to market expansion. Additionally, the variability in test performance and the potential for false-positive or false-negative results can impact diagnostic accuracy and patient outcomes, leading to concerns among healthcare providers and patients.

Market Opportunities:

The infectious disease IVD market presents numerous opportunities for innovation and expansion, particularly in the development of novel diagnostic technologies and test platforms. Advances in molecular diagnostics, including nucleic acid amplification tests and multiplex assays, offer improved sensitivity, specificity, and turnaround time for infectious disease detection.

Furthermore, the integration of artificial intelligence and machine learning algorithms into diagnostic platforms enhances data analysis and interpretation, leading to more accurate and actionable diagnostic insights. Moreover, the increasing adoption of point-of-care testing and decentralized diagnostic solutions enables timely diagnosis and treatment, particularly in underserved and remote areas.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Infectious Disease IVD Market from 2024 to 2031?
  • What are the Key Factors Driving the Growth of the Infectious Disease IVD Market?
  • Which Region Holds the Largest Market Share in the Infectious Disease IVD Market?
  • Who are the Key Players in the Global Infectious Disease IVD Market?
  • What Strategies are Adopted by Leading Companies to Sustain Growth in the Infectious Disease IVD Market?

Competitive Landscape and Business Strategies:

Leading companies in the infectious disease IVD market include Roche Diagnostics, Abbott Laboratories, and bioMerieux SA. These companies focus on product innovation, research and development, and strategic partnerships to maintain their competitive edge.

Strategies such as expanding product portfolios, geographic expansion, and mergers and acquisitions are employed to enhance market presence and gain a competitive advantage. Furthermore, collaborations with healthcare organizations, government agencies, and research institutions facilitate the development and commercialization of novel diagnostic solutions.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • bioMerieux SA
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • QIAGEN N.V.
  • Cepheid Inc.

Infectious Disease IVD Market Segmentation:

By Product Type:

  • Instruments
  • Reagents
  • Services

By Technology:

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Other Technologies

By Application:

  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Other Applications

By End-use:

  • Point of care
  • Central Laboratories
  • Other End-uses

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Technology Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Background

  • 3.1. Market Dynamics
    • 3.1.1. Drivers
    • 3.1.2. Restraints
    • 3.1.3. Opportunity
    • 3.1.4. Trends
  • 3.2. Scenario Forecast
    • 3.2.1. Demand in Optimistic Scenario
    • 3.2.2. Demand in Likely Scenario
    • 3.2.3. Demand in Conservative Scenario
  • 3.3. Opportunity Map Analysis
  • 3.4. Product Life Cycle Analysis
  • 3.5. Investment Feasibility Matrix
  • 3.6. PESTLE and Porter's Analysis
  • 3.7. Regulatory Landscape
    • 3.7.1. By Key Regions
    • 3.7.2. By Key Countries
  • 3.8. Regional Parent Market Outlook

4. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast, 2024-2031

  • 4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
  • 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2031
    • 4.2.1. Y-o-Y Growth Trend Analysis
    • 4.2.2. Absolute $ Opportunity Analysis

5. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Product Type

  • 5.1. Introduction / Key Findings
  • 5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2019-2023
  • 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
    • 5.3.1. Instruments
    • 5.3.2. Reagents
    • 5.3.3. Services
  • 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019-2023
  • 5.5. Absolute $ Opportunity Analysis By Product Type, 2024-2031

6. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Technology

  • 6.1. Introduction / Key Findings
  • 6.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2019-2023
  • 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2024-2031
    • 6.3.1. Immunoassay
    • 6.3.2. Molecular Diagnostics
    • 6.3.3. Microbiology
    • 6.3.4. Other Technologies
  • 6.4. Y-o-Y Growth Trend Analysis By Technology, 2019-2023
  • 6.5. Absolute $ Opportunity Analysis By Technology, 2024-2031

7. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Application

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2019-2023
  • 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2024-2031
    • 7.3.1. MRSA
    • 7.3.2. Streptococcus
    • 7.3.3. Clostridium Difficile
    • 7.3.4. Respiratory Virus
    • 7.3.5. TB and Drug-resistant TB
    • 7.3.6. Gonorrhea
    • 7.3.7. HPV
    • 7.3.8. HIV
    • 7.3.9. Hepatitis C
    • 7.3.10. Hepatitis B
    • 7.3.11. COVID-19
    • 7.3.12. Other Applications
  • 7.4. Y-o-Y Growth Trend Analysis By Application, 2019-2023
  • 7.5. Absolute $ Opportunity Analysis By Application, 2024-2031

8. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By End-use

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2019-2023
  • 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2024-2031
    • 8.3.1. Point of care
    • 8.3.2. Central Laboratories
    • 8.3.3. Other End-uses
  • 8.4. Y-o-Y Growth Trend Analysis By End-use, 2019-2023
  • 8.5. Absolute $ Opportunity Analysis By End-use, 2024-2031

9. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness Analysis By Region

10. North America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 10.2.1. By Country
      • 10.2.1.1. U.S.
      • 10.2.1.2. Canada
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End-use
  • 10.3. Market Attractiveness Analysis
    • 10.3.1. By Country
    • 10.3.2. By Product Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End-use
  • 10.4. Key Takeaways

11. Latin America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 11.2.1. By Country
      • 11.2.1.1. Brazil
      • 11.2.1.2. Mexico
      • 11.2.1.3. Rest of Latin America
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End-use
  • 11.3. Market Attractiveness Analysis
    • 11.3.1. By Country
    • 11.3.2. By Product Type
    • 11.3.3. By Technology
    • 11.3.4. By Application
    • 11.3.5. By End-use
  • 11.4. Key Takeaways

12. Europe Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 12.2.1. By Country
      • 12.2.1.1. Germany
      • 12.2.1.2. U.K.
      • 12.2.1.3. France
      • 12.2.1.4. Spain
      • 12.2.1.5. Italy
      • 12.2.1.6. Russia
      • 12.2.1.7. Rest of Europe
    • 12.2.2. By Product Type
    • 12.2.3. By Technology
    • 12.2.4. By Application
    • 12.2.5. By End-use
  • 12.3. Market Attractiveness Analysis
    • 12.3.1. By Country
    • 12.3.2. By Product Type
    • 12.3.3. By Technology
    • 12.3.4. By Application
    • 12.3.5. By End-use
  • 12.4. Key Takeaways

13. Asia Pacific Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 13.2.1. By Country
      • 13.2.1.1. China
      • 13.2.1.2. Japan
      • 13.2.1.3. India
      • 13.2.1.4. South Korea
      • 13.2.1.5. Australia
      • 13.2.1.6. Rest of APAC
    • 13.2.2. By Product Type
    • 13.2.3. By Technology
    • 13.2.4. By Application
    • 13.2.5. By End-use
  • 13.3. Market Attractiveness Analysis
    • 13.3.1. By Country
    • 13.3.2. By Product Type
    • 13.3.3. By Technology
    • 13.3.4. By Application
    • 13.3.5. By End-use
  • 13.4. Key Takeaways

14. Middle East and Africa Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 14.2.1. By Country
      • 14.2.1.1. South Africa
      • 14.2.1.2. Saudi Arabia
      • 14.2.1.3. UAE
      • 14.2.1.4. Israel
      • 14.2.1.5. Rest of MEA
    • 14.2.2. By Product Type
    • 14.2.3. By Technology
    • 14.2.4. By Application
    • 14.2.5. By End-use
  • 14.3. Market Attractiveness Analysis
    • 14.3.1. By Country
    • 14.3.2. By Product Type
    • 14.3.3. By Technology
    • 14.3.4. By Application
    • 14.3.5. By End-use
  • 14.4. Key Takeaways

15. Key Countries Infectious Disease In-vitro Diagnostics Market Analysis

  • 15.1. U.S.
    • 15.1.1. Pricing Analysis
    • 15.1.2. Market Share Analysis, 2024
      • 15.1.2.1. By Product Type
      • 15.1.2.2. By Technology
      • 15.1.2.3. By Application
      • 15.1.2.4. By End-use
  • 15.2. Canada
    • 15.2.1. Pricing Analysis
    • 15.2.2. Market Share Analysis, 2024
      • 15.2.2.1. By Product Type
      • 15.2.2.2. By Technology
      • 15.2.2.3. By Application
      • 15.2.2.4. By End-use
  • 15.3. Brazil
    • 15.3.1. Pricing Analysis
    • 15.3.2. Market Share Analysis, 2024
      • 15.3.2.1. By Product Type
      • 15.3.2.2. By Technology
      • 15.3.2.3. By Application
      • 15.3.2.4. By End-use
  • 15.4. Mexico
    • 15.4.1. Pricing Analysis
    • 15.4.2. Market Share Analysis, 2024
      • 15.4.2.1. By Product Type
      • 15.4.2.2. By Technology
      • 15.4.2.3. By Application
      • 15.4.2.4. By End-use
  • 15.5. Germany
    • 15.5.1. Pricing Analysis
    • 15.5.2. Market Share Analysis, 2024
      • 15.5.2.1. By Product Type
      • 15.5.2.2. By Technology
      • 15.5.2.3. By Application
      • 15.5.2.4. By End-use
  • 15.6. U.K.
    • 15.6.1. Pricing Analysis
    • 15.6.2. Market Share Analysis, 2024
      • 15.6.2.1. By Product Type
      • 15.6.2.2. By Technology
      • 15.6.2.3. By Application
      • 15.6.2.4. By End-use
  • 15.7. France
    • 15.7.1. Pricing Analysis
    • 15.7.2. Market Share Analysis, 2024
      • 15.7.2.1. By Product Type
      • 15.7.2.2. By Technology
      • 15.7.2.3. By Application
      • 15.7.2.4. By End-use
  • 15.8. Spain
    • 15.8.1. Pricing Analysis
    • 15.8.2. Market Share Analysis, 2024
      • 15.8.2.1. By Product Type
      • 15.8.2.2. By Technology
      • 15.8.2.3. By Application
      • 15.8.2.4. By End-use
  • 15.9. Italy
    • 15.9.1. Pricing Analysis
    • 15.9.2. Market Share Analysis, 2024
      • 15.9.2.1. By Product Type
      • 15.9.2.2. By Technology
      • 15.9.2.3. By Application
      • 15.9.2.4. By End-use
  • 15.10. Russia
    • 15.10.1. Pricing Analysis
    • 15.10.2. Market Share Analysis, 2024
      • 15.10.2.1. By Product Type
      • 15.10.2.2. By Technology
      • 15.10.2.3. By Application
      • 15.10.2.4. By End-use
  • 15.11. China
    • 15.11.1. Pricing Analysis
    • 15.11.2. Market Share Analysis, 2024
      • 15.11.2.1. By Product Type
      • 15.11.2.2. By Technology
      • 15.11.2.3. By Application
      • 15.11.2.4. By End-use
  • 15.12. Japan
    • 15.12.1. Pricing Analysis
    • 15.12.2. Market Share Analysis, 2024
      • 15.12.2.1. By Product Type
      • 15.12.2.2. By Technology
      • 15.12.2.3. By Application
      • 15.12.2.4. By End-use
  • 15.13. India
    • 15.13.1. Pricing Analysis
    • 15.13.2. Market Share Analysis, 2024
      • 15.13.2.1. By Product Type
      • 15.13.2.2. By Technology
      • 15.13.2.3. By Application
      • 15.13.2.4. By End-use
  • 15.14. South Korea
    • 15.14.1. Pricing Analysis
    • 15.14.2. Market Share Analysis, 2024
      • 15.14.2.1. By Product Type
      • 15.14.2.2. By Technology
      • 15.14.2.3. By Application
      • 15.14.2.4. By End-use
  • 15.15. Australia
    • 15.15.1. Pricing Analysis
    • 15.15.2. Market Share Analysis, 2024
      • 15.15.2.1. By Product Type
      • 15.15.2.2. By Technology
      • 15.15.2.3. By Application
      • 15.15.2.4. By End-use
  • 15.16. South Africa
    • 15.16.1. Pricing Analysis
    • 15.16.2. Market Share Analysis, 2024
      • 15.16.2.1. By Product Type
      • 15.16.2.2. By Technology
      • 15.16.2.3. By Application
      • 15.16.2.4. By End-use
  • 15.17. Saudi Arabia
    • 15.17.1. Pricing Analysis
    • 15.17.2. Market Share Analysis, 2024
      • 15.17.2.1. By Product Type
      • 15.17.2.2. By Technology
      • 15.17.2.3. By Application
      • 15.17.2.4. By End-use
  • 15.18. UAE
    • 15.18.1. Pricing Analysis
    • 15.18.2. Market Share Analysis, 2024
      • 15.18.2.1. By Product Type
      • 15.18.2.2. By Technology
      • 15.18.2.3. By Application
      • 15.18.2.4. By End-use
  • 15.19. Israel
    • 15.19.1. Pricing Analysis
    • 15.19.2. Market Share Analysis, 2024
      • 15.19.2.1. By Product Type
      • 15.19.2.2. By Technology
      • 15.19.2.3. By Application
      • 15.19.2.4. By End-use

16. Market Structure Analysis

  • 16.1. Competition Dashboard
  • 16.2. Competition Benchmarking
  • 16.3. Market Share Analysis of Top Players
    • 16.3.1. By Regional
    • 16.3.2. By Product Type
    • 16.3.3. By Technology
    • 16.3.4. By Application
    • 16.3.5. By End-use

17. Competition Analysis

  • 17.1. Competition Deep Dive
    • 17.1.1. Becton, Dickinson and Company
      • 17.1.1.1. Overview
      • 17.1.1.2. Product Portfolio
      • 17.1.1.3. Profitability by Market Segments
      • 17.1.1.4. Sales Footprint
      • 17.1.1.5. Strategy Overview
        • 17.1.1.5.1. Marketing Strategy
    • 17.1.2. bioMerieux SA
      • 17.1.2.1. Overview
      • 17.1.2.2. Product Portfolio
      • 17.1.2.3. Profitability by Market Segments
      • 17.1.2.4. Sales Footprint
      • 17.1.2.5. Strategy Overview
        • 17.1.2.5.1. Marketing Strategy
    • 17.1.3. Abbott
      • 17.1.3.1. Overview
      • 17.1.3.2. Product Portfolio
      • 17.1.3.3. Profitability by Market Segments
      • 17.1.3.4. Sales Footprint
      • 17.1.3.5. Strategy Overview
        • 17.1.3.5.1. Marketing Strategy
    • 17.1.4. Quidel Corporation
      • 17.1.4.1. Overview
      • 17.1.4.2. Product Portfolio
      • 17.1.4.3. Profitability by Market Segments
      • 17.1.4.4. Sales Footprint
      • 17.1.4.5. Strategy Overview
        • 17.1.4.5.1. Marketing Strategy
    • 17.1.5. OraSure Technologies, Inc
      • 17.1.5.1. Overview
      • 17.1.5.2. Product Portfolio
      • 17.1.5.3. Profitability by Market Segments
      • 17.1.5.4. Sales Footprint
      • 17.1.5.5. Strategy Overview
        • 17.1.5.5.1. Marketing Strategy
    • 17.1.6. Hologic Inc.
      • 17.1.6.1. Overview
      • 17.1.6.2. Product Portfolio
      • 17.1.6.3. Profitability by Market Segments
      • 17.1.6.4. Sales Footprint
      • 17.1.6.5. Strategy Overview
        • 17.1.6.5.1. Marketing Strategy
    • 17.1.7. Cepheid
      • 17.1.7.1. Overview
      • 17.1.7.2. Product Portfolio
      • 17.1.7.3. Profitability by Market Segments
      • 17.1.7.4. Sales Footprint
      • 17.1.7.5. Strategy Overview
        • 17.1.7.5.1. Marketing Strategy
    • 17.1.8. Qiagen
      • 17.1.8.1. Overview
      • 17.1.8.2. Product Portfolio
      • 17.1.8.3. Profitability by Market Segments
      • 17.1.8.4. Sales Footprint
      • 17.1.8.5. Strategy Overview
        • 17.1.8.5.1. Marketing Strategy
    • 17.1.9. F. Hoffmann-La Roche Ltd.
      • 17.1.9.1. Overview
      • 17.1.9.2. Product Portfolio
      • 17.1.9.3. Profitability by Market Segments
      • 17.1.9.4. Sales Footprint
      • 17.1.9.5. Strategy Overview
        • 17.1.9.5.1. Marketing Strategy
    • 17.1.10. Siemens Healthcare GmbH
      • 17.1.10.1. Overview
      • 17.1.10.2. Product Portfolio
      • 17.1.10.3. Profitability by Market Segments
      • 17.1.10.4. Sales Footprint
      • 17.1.10.5. Strategy Overview
        • 17.1.10.5.1. Marketing Strategy
    • 17.1.11. Bio-Rad Laboratories, Inc.
      • 17.1.11.1. Overview
      • 17.1.11.2. Product Portfolio
      • 17.1.11.3. Profitability by Market Segments
      • 17.1.11.4. Sales Footprint
      • 17.1.11.5. Strategy Overview
        • 17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology